Literature DB >> 10718366

High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.

M Watanabe1, M Chigusa, H Takahashi, J Nakamura, H Tanaka, T Ohno.   

Abstract

The ascites of a 78-yr-old Japanese woman with cholangiocarcinoma was used for a primary culture. An established new cell line (designated TK from the Japanese description of cholangiocarcinoma; Tankan-gann) showed conspicuous tumor marker production. A high level of circulating serum tumor markers; carbohydrate antigen (CA) 19-9, 32,000 U/ml; CA50, 6900 U/ml; and carcinoembryonic antigen (CEA), 300 ng/ml (on an average from 10(6) cells/ml for 3 d culture) were detected in the tissue culture supernatant. With an inoculum of 2 x 10(7) TK cells, nude mice progressively developed tumors. The histological features of the tumors forming in nude mice showed well-differentiated adenocarcinoma. Within the tumor mass, large amounts of extra cellular fluid retained approximately 590,000 U/ml of CA19-9, 200,000 U/ml of CA50, and 2000 ng/ml of CEA. Alpha-feto-protein was undetectable in the TK culture supernatant. There are few cholangiocarcinoma cell lines producing stable human tumor markers. Newly established TK cells derived from cholangiocarcinoma showed a stable production of serum tumor markers in vivo and in vitro. The changes in the tumor marker secretion ratios were shown to be dependent upon type of tumor cells, i.e., whether they are in vitro or in vivo. These features make TK cells a valuable tool for studying tumor markers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718366     DOI: 10.1290/1071-2690(2000)036<0104:HLOCCA>2.0.CO;2

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  17 in total

1.  New scoring system using tumor markers in diagnosing patients with moderate pericardial effusions.

Authors:  K K Koh; H H In; K H Lee; E J Kim; C H Cho; S K Cho; S S Kim; S S Cho; W K Baek; S H Jin; Y C Ju; J J Kim; C S Park; H S Nam; Y H Lee
Journal:  Int J Cardiol       Date:  1997-08-29       Impact factor: 4.164

2.  Alpha-fetoprotein as a marker of embryo-specific differentiations in normal and tumor tissues.

Authors:  G I Abelev
Journal:  Transplant Rev       Date:  1974

3.  Cancer of the extrahepatic bile duct: a clinicopathologic study of immunohistochemistry for CEA, CA19-9, and p21.

Authors:  K Yamaguchi; M Enjoji; F Nakayama
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

4.  Tumor markers in the diagnosis of malignant serous effusions.

Authors:  S Cascinu; E Del Ferro; I Barbanti; M Ligi; A Fedeli; G Catalano
Journal:  Am J Clin Oncol       Date:  1997-06       Impact factor: 2.339

5.  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

Authors:  M Miyagiwa; T Ichida; T Tokiwa; J Sato; H Sasaki
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

6.  Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  J K Ramage; A Donaghy; J M Farrant; R Iorns; R Williams
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

7.  Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Authors:  Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

8.  Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma.

Authors:  S Nakamura; S Suzuki; T Sakaguchi; A Serizawa; H Konno; S Baba; S Baba; H Muro
Journal:  Cancer       Date:  1996-10-15       Impact factor: 6.860

9.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

10.  A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions.

Authors:  H Yano; A Iemura; M Haramaki; S Momosaki; S Ogasawara; K Higaki; M Kojiro
Journal:  J Hepatol       Date:  1996-04       Impact factor: 25.083

View more
  5 in total

1.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Authors:  Xing-Lei Qin; Zhuo-Ren Wang; Jing-Sen Shi; Min Lu; Lin Wang; Quan-Ru He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 2.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

3.  Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Authors:  Panthip Rattanasinganchan; Kawin Leelawat; Sa-ard Treepongkaruna; Chintana Tocharoentanaphol; Somboon Subwongcharoen; Tuangporn Suthiphongchai; Rutaiwan Tohtong
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 4.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

5.  Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.

Authors:  Sukanya Luang; Karuntarat Teeravirote; Waraporn Saentaweesuk; Prasertsri Ma-In; Atit Silsirivanit
Journal:  Medicina (Kaunas)       Date:  2020-11-16       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.